𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Hepatitis B virus precore mutants in HBeAg carriers with chronic hepatitis treated with interferon

✍ Scribed by P. Lampertico; A. Manzin; M. G. Rumi; S. Paolucci; E. Del Ninno; M. Dementi; M. Colombo

Book ID
119836560
Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
551 KB
Volume
2
Category
Article
ISSN
1352-0504

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Absence of hepatitis B virus precore mut
Absence of hepatitis B virus precore mutants in patients with chronic hepatitis B responding to interferon-α
✍ Jianye Xu; David Brown; Tim Harrison; Yue Lin; Geoffrey Dusheiko 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 614 KB

Precore defective HBV mutants may gradually prevail because of immune selection and explain spontaneous seroconversion from HBeAg to anti-HBe in HBV carriers. We have analyzed whether the presence of precore HBV mutants is a determinant of responsiveness to interferon-a therapy. Fifteen carriers (ni

Efficacy of lamivudine in patients with
Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis BB
✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60

Reactivation of precore mutant hepatitis
Reactivation of precore mutant hepatitis B virus in chemotherapy-treated patients
✍ Ming-Shen Dai; Jang-Jih Lu; Yeu-Chin Chen; Cherng-Lih Perng; Tsu-Yi Chao 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 2 views

## BACKGROUND. A point mutation from G to A at nucleotide (nt) 1896 of the precore region of hepatitis B virus (HBV) DNA has been shown to be associated with fulminant and severe hepatitis. Further studies have suggested that this point mutation, together with additional mutations in the precore p